We Offer Worldwide Shipping
Login Wishlist

Trillin

$108

  • Brand : BIOFRON

  • Catalogue Number : BD-P0583

  • Specification : 98.0%(HPLC)

  • CAS number : 14144-06-0

  • Formula : C33H52O8

  • Molecular Weight : 576.76

  • PUBCHEM ID : 11827970

  • Volume : 20mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BD-P0583

Analysis Method

HPLC,NMR,MS

Specification

98.0%(HPLC)

Storage

2-8°C

Molecular Weight

576.76

Appearance

White powder

Botanical Source

Trillium tschonoskii Maxim/Dioscorea spp., Yucca spp., Trillium terrestris, Trillium kamtschaticum, Trillium erectum, Trigonella foenum-graecum and Paris polyphylla

Structure Type

Steroids

Category

Standards;Natural Pytochemical;API

SMILES

CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CC=C6C5(CCC(C6)OC7C(C(C(C(O7)CO)O)O)O)C)C)C)OC1

Synonyms

Diosgenin 3-b-D-glucoside/β-D-Glucopyranoside, (3β,25R)-spirost-5-en-3-yl/Diosgenin 3-O-b-D-glucopyranoside/PolyphyllinA/Diosgenin b-D-glucoside/Polyphyllin A/Funkioside A/Diosgenin 3-glucoside/Collettinside I/Melongoside B/Diosgenin glucoside/(25R)-3β-(β-D-Glucopyranosyloxy)spirost-5-ene/(25R)-3b-(b-D-Glucopyranosyloxy)spirost-5-ene/Disogluside/Prosapogenin D'3/Lilioglycoside A/Alliumoside A/Polygonatoside A/Trillin/(3β,25R)-Spirost-5-en-3-yl β-D-glucopyranoside/Collettiside I

IUPAC Name

(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[(1S,2S,4S,5'R,6R,7S,8R,9S,12S,13R,16S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-yl]oxyoxane-3,4,5-triol

Applications

Diosgenin glucoside, a saponin compound extracted from Tritulus terrestris L., provides neuroprotection by regulating microglial M1 polarization. Diosgenin glucoside protects against spinal cord injury by regulating autophagy and alleviating apoptosis [1][2].

Density

1.3±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

380.2±32.9 °C

Boiling Point

705.1±60.0 °C at 760 mmHg

Melting Point

InChl

InChI=1S/C33H52O8/c1-17-7-12-33(38-16-17)18(2)26-24(41-33)14-23-21-6-5-19-13-20(8-10-31(19,3)22(21)9-11-32(23,26)4)39-30-29(37)28(36)27(35)25(15-34)40-30/h5,17-18,20-30,34-37H,6-16H2,1-4H3/t17-,18+,20?,21-,22+,23+,24+,25-,26+,27-,28+,29-,30-,31+,32+,33-/m1/s1

InChl Key

WXMARHKAXWRNDM-VVWJQRNDSA-N

WGK Germany

RID/ADR

HS Code Reference

2938900000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:14144-06-0) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

30072674

Abstract

Spinal cord injury (SCI) is a severe traumatic lesion of central nervous system (CNS) with only a limited number of restorative therapeutic options. Diosgenin glucoside (DG), a major bioactive ingredient of Trillium tschonoskii Max., possesses neuroprotective effects through its antioxidant and anti-apoptotic functions. In this study, we investigated the therapeutic benefit and underlying mechanisms of DG treatment in SCI. We found that in Sprague-Dawley rats with traumatic SCI, the expressions of autophagy marker Light Chain 3 (LC3) and Beclin1 were decreased with concomitant accumulation of autophagy substrate protein p62 and ubiquitinated proteins, indicating an impaired autophagic activity. DG treatment, however, significantly attenuated p62 expression and upregulated the Rheb/mTOR signaling pathway (evidenced as Ras homolog enriched in brain) due to the downregulation of miR-155-3p. We also observed significantly less tissue injury and edema in the DG-treated group, leading to appreciable functional recovery compared to that of the control group. Overall, the observed neuroprotection afforded by DG treatment warrants further investigation on its therapeutic potential in SCI.

KEYWORDS

Rheb/mTOR signal pathway; apoptosis; autophagy; diosgenin glucoside; miR-155-3p; spinal cord injury

Title

Diosgenin Glucoside Protects against Spinal Cord Injury by Regulating Autophagy and Alleviating Apoptosis.

Author

Chen XB1,2, Wang ZL3, Yang QY4, Zhao FY5, Qin XL6, Tang XE7, Du JL8, Chen ZH9, Zhang K10, Huang FJ11.

Publish date

2018 Aug 2

PMID

28623715

Abstract

The selective suppression of inflammatory factors in activated microglia, rather than totally inhibiting their activation, might be an effective means of slowing the progression of certain neurodegenerative diseases. Diosgenin glucoside (Dios) is a saponin compound extracted from Tritulus terrestris L. We found that Dios suppressed the synthesis of molecules that promote inflammation (M1 markers, such as NO, IL-6, and TNF-α) in rat microglia and BV-2 cells induced with lipopolysaccharides (LPS). In contrast, Dios had no effects on the cellular production of anti-inflammatory factors (M2 markers, such as IL-10, IL-1Rα and CD206) in LPS and IL-4 treated microglia. Dios repressed IκB-α, ERK MAPK and p38 MAPK phosphorylation, but did not affect JNK in LPS-activated microglia. We also found that conditioned medium obtained from cultures of BV-2 cells incubated with Dios plus LPS was markedly less neurotoxic than conditioned medium obtained from cultures of BV-2 cells incubated with LPS alone. In conclusion, this study demonstrated that Dios can selectively suppress the production/expression of pro-inflammatory M1 markers by activated microglia, without affecting M2 markers, and might provide neuroprotection by regulating microglial M1 polarization. Our results suggest that Dios can be used in treatment of various neuroinflammatory diseases mediated by microglia.

Copyright © 2017. Published by Elsevier B.V.

KEYWORDS

Diosgenin glucoside; Inflammation; Microglia; Neuroprotection

Title

Diosgenin glucoside provides neuroprotection by regulating microglial M1 polarization.

Author

Wang S1, Wang F2, Yang H1, Li R2, Guo H2, Hu L3.

Publish date

2017 Sep

PMID

3559397

Abstract

The predominantly beta-anomer of diosgenin glucoside (DG) was synthesized and its effects on cholesterol homeostasis were tested in monkeys. Cynomolgus macaques (Macaca fascicularis) were fed, during two 3-week periods, a semipurified diet with 0.1% cholesterol and a similar ration containing 1% DG, respectively. A Chow diet was given for 5 weeks between the experimental periods. Cholesterol and bile acid balance were analyzed during the last week of each semipurified diet. Diosgenin glucoside reduced cholesterolemia from 292 mg/dl to 172 mg/dl, decreased intestinal absorption of exogenous cholesterol from 62.4% to 26.0%, and increased secretion of endogenous cholesterol from -0.8 to 93.5 mg/day. The fecal excretion of neutral steroids rose from 40.7 to 157.3 mg/day; that of bile acids changed, nonsignificantly, from 23.1 to 16.0 mg/day. The cholesterol balance was -44 mg/day in the control period, and 88 mg/day in the DG-fed animals. No toxic signs were observed. Thus, when long-term studies demonstrate that the glucoside is well tolerated, DG and other synthetic glycosides with similar activities may be of use in the management of hypercholesterolemia and atherosclerosis.

Title

Effects of synthetic glycosides on steroid balance in Macaca fascicularis.

Author

Malinow MR, Elliott WH, McLaughlin P, Upson B.

Publish date

1987 Jan